A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.

"because we anticipated differences in gene expression and distribution according to tumor histology the dataset was first separated into squamous and non-squamous subsets with scaling and averaging across genes performed separately between the two groups fican-oscar top-performer in the os sub-challenge a single linear regression model using a novel o ptimal s ubset ca rdinality r egression ( oscar ) l0-quasinorm regularization was generated using the r package available at https://github com/syksy/oscar/releases/tag/v0 6 1 [ ]."

"because we anticipated differences in gene expression and distribution according to tumor histology the dataset was first separated into squamous and non-squamous subsets with scaling and averaging across genes performed separately between the two groups fican-oscar top-performer in the os sub-challenge a single linear regression model using a novel o ptimal s ubset ca rdinality r egression ( oscar ) l0-quasinorm regularization was generated using the r package available at https://github com/syksy/oscar/releases/tag/v0 6 1 [ ]."

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsMM, HC, and HYL are employees of Bristol Myers Squibb. MIM has received lecture and/or advisory board fees from Boehringer Ingelheim, Bristol Myers Squibb, MSD, Takeda, Bayer, Amgen, Roche, and Aiforia Technologies Oy. WY is a shareholder of Aginome Scientific. JG is an employee of Tempus Labs. SSG is the recipient of a fellowship from the Sara Elizabeth O’Brien Trust. JS, SC, and WJG are employees and shareholders of Bristol Myers Squibb. BGV received consulting fees from GeneCentric Therapeutics. DPC has received advisory board fees, consulting fees, presentation fees, or consulting fees from Regeneron, Novartis, AbbVie, AstraZeneca, Bristol Myers Squibb, Roche, Arcus Biosciences, Mirati, Iovance Biotherapeutics, Pfizer, Onc Live, InThought, Glaxo-Smith Kline, Intellisphere, Sanofi, Merck KGgA, Merck/EMD Serono, Johnson & Johnson, Jazz, Janssen, Curio Science, PDD development, G1 Therapeutics, OncoHost, Eisai, Flame Biosciences, Novocure, Merck, Daiichi Sankyo, and Boehringer Ingelheim. Other authors declare that they do not have competing interests. Competing interests MM, HC, and HYL are employees of Bristol Myers Squibb. MIM has received lecture and/or advisory board fees from Boehringer Ingelheim, Bristol Myers Squibb, MSD, Takeda, Bayer, Amgen, Roche, and Aiforia Technologies Oy. WY is a shareholder of Aginome Scientific. JG is an employee of Tempus Labs. SSG is the recipient of a fellowship from the Sara Elizabeth O’Brien Trust. JS, SC, and WJG are employees and shareholders of Bristol Myers Squibb. BGV received consulting fees from GeneCentric Therapeutics. DPC has received advisory board fees, consulting fees, presentation fees, or consulting fees from Regeneron, Novartis, AbbVie, AstraZeneca, Bristol Myers Squibb, Roche, Arcus Biosciences, Mirati, Iovance Biotherapeutics, Pfizer, Onc Live, InThought, Glaxo-Smith Kline, Intellisphere, Sanofi, Merck KGgA, Merck/EMD Serono, Johnson & Johnson, Jazz, Janssen, Curio Science, PDD development, G1 Therapeutics, OncoHost, Eisai, Flame Biosciences, Novocure, Merck, Daiichi Sankyo, and Boehringer Ingelheim. Other authors declare that they do not have competing interests."

"Funding TDL was funded by the Finnish Cancer Institute and the Finnish Cultural foundation as a FICAN Cancer Researcher. ASH received funding from the University of Turku Graduate School (MATTI), the Academy of Finland (grants 310507, 313267, and 326238), the Cancer Society of Finland, and the Sigrid Jusélius Foundation. MIM received funding from the Finnish Medical Foundation. TM received funding from the Academy of Finland. FF was supported by the Austrian Science Fund (FWF) [T 974-B30] and the Oesterreichische Nationalbank (OeNB) [18496]. OL-S was supported by the Department of Biomedical Engineering, Eindhoven University of Technology. WW, JB, and JT were supported by an ERC Starting Grant (DrugComb, No. 716063), the Academy of Finland (No. 317680), and the Sigrid Jusélius Foundation. WW was funded by the FIMM-EMBL International PhD programme, Doctoral Programme of Biomedicine at the University of Helsinki, Cancer Foundation Finland, K. Albin Johanssons stiftelse, Ida Montinin Säätiö, Orion Research Foundation sr, and Biomedicum Helsinki Foundation. EV was supported by the Academy of Finland (No. 328437), the iCAN Digital Precision Cancer Medicine Flagship (No. 320185 Academy of Finland), and the CAN-PRO Translational Cancer Medicine Research Program Unit. Data analysis resources were provided by the CSC – IT Center for Science, Finland. JK received funding from the Department of Defense (Lung Cancer Research Program Concept Award LC180633) and was the recipient of a SITC-AstraZeneca Lung Cancer Clinical Fellowship (SPS256666). LY and YL received PACT funding through FNIH. MT received funding from the NIH. SSG was the recipient of the Sara Elizabeth O’Brien Trust Fellowship. ADS received funding from the NCI (K99CA248953) and the Human Immunome Project (MP19-02–190). DB received a grant from the Sidra Medicine Internal Funds (SDR400123). MC received the following grant from AIRC: IG 2018 ID 21846. The study was supported by Bristol Myers Squibb."

"Trial registration : CheckMate 026; NCT02041533, registered January 22, 2014. Trial registration"